2 Followers SGX:BFK - Pharmesis Intl (SGD 0.225) PHARMESIS INTERNATIONAL LTD.
Sector: Health Technology, Industry: Pharmaceuticals: Generic

Add to WatchList

See related symbol P31


SGD 0.225    +0.0 (+0%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

13 Dec 2019


Overview

13 Dec 2019

52 Wk Range: 0.115 - 0.45

Day's Range: 0.225 - 0.225

Last Volume: 0

Current Yield: 0%

Projected Yield: 0%

Future Yield: [Friends Only]

Dividend Strength: [Friends Only]

13 Dec 2019

Metric BFK S.Median
Beta 0.17 0.19
VaR 73.74 33.08
E.Shortfall 128.3 44.38
Liquidity 504.4 12.06K

Fundamental

11 Dec 2019

PE: NA

Market Cap: 5.2M

Price Over Book: 0.382

Price Over Sales: 0.63

Return On Assets: -6.7%

Return On Equity: -9.3%

NAV Over Price: [Friends Only]

General

CEO: Xue Dan Wu

Founded Year: 2003

Headquarters: Chengdu

Shares Outstanding: 23M

Security Type: Stock

Useful Links
Homepage

Description

Pharmesis International Ltd. Is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates through the following segments: Western Drugs, Traditional Chinese Medicine (TCM) Formulated Drugs, and Distribution. The Western Drugs segment involves in the chemically formulated drugs and is marketed under the Kinna brand. The TCM segment offers traditional Chinese medicine and is marketed under the Longlife brand. The Distribution segment consists of agency products and internally manufactured products which are marketed through the distribution arm. The company was founded on September 29, 2003 and is headquartered in Chengdu, China.